Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia

Richter syndrome: pathogenesis and management

(2016) Davide Rossi et al.   SEMINARS IN ONCOLOGY

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

(2016) Jan A. Burger et al.   Nature Communications

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) B. Eichhorst et al.   ANNALS OF ONCOLOGY

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

(2015) Kami J. Maddocks et al.   JAMA Oncology

How we treat Richter syndrome

(2014) S. A. Parikh et al.   BLOOD

Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients

(2013) Sameer A. Parikh et al.   BRITISH JOURNAL OF HAEMATOLOGY

The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation

(2011) D. Rossi et al.   BLOOD

Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome

(2009) D. Rossi et al.   CLINICAL CANCER RESEARCH

Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome

(2008) Davide Rossi et al.   BRITISH JOURNAL OF HAEMATOLOGY